Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.
about
Borrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infectionRecurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian familyDepletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.A self-assembling peptide acting as an immune adjuvant.C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequencesRole of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharideHuman factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH bindingMarginal zone B cells: virtues of innate-like antibody-producing lymphocytes.Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens.Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cellsCancer vaccines and carbohydrate epitopes.Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunizationFusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus.A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response.Complement: an overview for the clinician.Contribution of Chinese Pekin duck complement component C3d-P29 repeats to enhancement of Th2-biased immune responses against NDV F gene induced by DNA immunization.Cloning of a gene fragment encoding chicken complement component C3d with expression and immunogenicity of Newcastle disease virus F gene-C3d fusion protein.Mannan-binding lectin deficiency modulates the humoral immune response dependent on the genetic environment.Novel function of complement C3d as an autologous helper T-cell target.
P2860
Q24684907-5922960D-4EE8-48A6-AC57-0C15192325D1Q28291779-5E4E2026-9C18-440C-973B-E3BA2D47FE15Q33558995-7A729A76-102F-4C47-864E-6D690E53699EQ33640064-5A6AF308-969F-44C0-9063-6CB3917CDB74Q34099087-54CF4737-38AE-4740-953F-1FE37AD90A51Q34111798-70F4BFAC-8BA3-4C32-B938-98D12EF52CAEQ34237895-FA9F5151-BCA1-4954-A3C9-FCFDF5E4B333Q34324243-DCCA7982-0090-4AC1-AF51-ADD4FE0348A4Q34466693-E1E7311C-14EF-4AB6-86B8-D0F961EBE573Q34894134-EEF56E28-4363-473E-BD62-893A52D8FA85Q34999724-727041E4-2852-45D4-B28D-E6852D6A0F5DQ35071379-9868186B-8330-4409-89FD-144658FAEDD0Q35525289-8387B72A-8778-4B3C-A4B7-2F32A1B58557Q36066222-F614A09F-6A5F-4C78-A50D-AAB09B4B0E12Q36960498-16E46F14-CDDD-43B2-9332-4F30F2B5205BQ36979271-7A0EEF2D-306E-49D6-A498-EE103CDD5FF1Q37128643-7AFAF695-B0B1-4BD3-9B1E-ACAA81CC7460Q37422543-1E492098-E010-4455-97CA-7841DC1C7CF1Q37773306-CEF0B8DC-A929-4BF9-A2E4-EB901A1BE924Q38515940-77CD1B71-11E2-466E-AB96-9E4866538B84Q39901594-3C61F12D-D6AA-49B8-AC86-DA23C0B55B29Q45390992-9E065DE3-D31B-44AE-8668-BED002707E78Q47707908-9ADF0FB3-AD86-43DD-8C9A-695AC9B9710BQ51897183-80FA0BE3-3C1C-44EA-AA0D-2A2D9D9FDC2C
P2860
Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Increased immunogenicity and i ...... pe 14 capsular polysaccharide.
@ast
Increased immunogenicity and i ...... pe 14 capsular polysaccharide.
@en
Increased immunogenicity and i ...... pe 14 capsular polysaccharide.
@nl
type
label
Increased immunogenicity and i ...... pe 14 capsular polysaccharide.
@ast
Increased immunogenicity and i ...... pe 14 capsular polysaccharide.
@en
Increased immunogenicity and i ...... pe 14 capsular polysaccharide.
@nl
prefLabel
Increased immunogenicity and i ...... pe 14 capsular polysaccharide.
@ast
Increased immunogenicity and i ...... pe 14 capsular polysaccharide.
@en
Increased immunogenicity and i ...... pe 14 capsular polysaccharide.
@nl
P2093
P2860
P1476
Increased immunogenicity and i ...... pe 14 capsular polysaccharide.
@en
P2093
C C Connolly
J Mitsuyoshi
P2860
P304
P356
10.1128/IAI.69.5.3031-3040.2001
P407
P577
2001-05-01T00:00:00Z